Tags

Type your tag names separated by a space and hit enter

Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum.
Psychiatry Res 2011; 192(3):140-6PR

Abstract

We aimed to assess the association between core cerebrospinal fluid (CSF) biomarkers, regional brain atrophy and clinical severity in the Alzheimer's disease (AD) continuum, as well as to investigate how cognitive reserve (CR) may modulate these putative associations. Forty-nine subjects (11 controls, 10 patients with subjective memory complaints, 19 with mild cognitive impairment and 9 mild AD) underwent lumbar puncture and high-resolution magnetic resonance imaging (MRI). CSF amyloid-β(1-42) (Aβ(1-42)), total tau (t-tau) and phosphorylated tau (p-tau(181)) were determined. Voxel-based morphometry (VBM) was applied and multiple regression analyses for the whole sample were carried out. Clinical severity was adjusted using the Clinical Dementia Rating Sum of Boxes score (CDR-SB). A negative correlation between t-tau levels and grey matter (GM) volume in temporo-parietal regions was found, regardless of CDR-SB score. In contrast, the negative correlation between p-tau(181) and GM volume was largely explained by clinical severity, except in the posterior cingulate cortex. CR did not significantly modify these correlations. Aβ(1-42) levels were not related to GM volume but were related to clinical severity, an association that was attenuated when CR was considered. In conclusion, the present findings reflect that t-tau CSF concentrations are associated with GM atrophy in neuropathologically relevant areas across the AD continuum, whereas the p-tau(181) association is largely dependent on the degree of clinical severity. The relationship between CSF Aβ(1-42) and clinical severity seems to be modulated by CR, suggesting that there may be subjects with pathological levels of Aβ(1-42) and high CR estimates who remain clinically asymptomatic.

Authors+Show Affiliations

Alzheimer's disease and other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Catalonia, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21546220

Citation

Solé-Padullés, Cristina, et al. "Association Between Cerebrospinal Fluid Tau and Brain Atrophy Is Not Related to Clinical Severity in the Alzheimer's Disease Continuum." Psychiatry Research, vol. 192, no. 3, 2011, pp. 140-6.
Solé-Padullés C, Lladó A, Bartrés-Faz D, et al. Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. Psychiatry Res. 2011;192(3):140-6.
Solé-Padullés, C., Lladó, A., Bartrés-Faz, D., Fortea, J., Sánchez-Valle, R., Bosch, B., ... Rami, L. (2011). Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. Psychiatry Research, 192(3), pp. 140-6. doi:10.1016/j.pscychresns.2010.12.001.
Solé-Padullés C, et al. Association Between Cerebrospinal Fluid Tau and Brain Atrophy Is Not Related to Clinical Severity in the Alzheimer's Disease Continuum. Psychiatry Res. 2011 Jun 30;192(3):140-6. PubMed PMID: 21546220.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. AU - Solé-Padullés,Cristina, AU - Lladó,Albert, AU - Bartrés-Faz,David, AU - Fortea,Juan, AU - Sánchez-Valle,Raquel, AU - Bosch,Beatriz, AU - Antonell,Anna, AU - Molinuevo,José Luis, AU - Rami,Lorena, Y1 - 2011/05/04/ PY - 2010/07/28/received PY - 2010/12/01/revised PY - 2010/12/02/accepted PY - 2011/5/7/entrez PY - 2011/5/7/pubmed PY - 2011/7/13/medline SP - 140 EP - 6 JF - Psychiatry research JO - Psychiatry Res VL - 192 IS - 3 N2 - We aimed to assess the association between core cerebrospinal fluid (CSF) biomarkers, regional brain atrophy and clinical severity in the Alzheimer's disease (AD) continuum, as well as to investigate how cognitive reserve (CR) may modulate these putative associations. Forty-nine subjects (11 controls, 10 patients with subjective memory complaints, 19 with mild cognitive impairment and 9 mild AD) underwent lumbar puncture and high-resolution magnetic resonance imaging (MRI). CSF amyloid-β(1-42) (Aβ(1-42)), total tau (t-tau) and phosphorylated tau (p-tau(181)) were determined. Voxel-based morphometry (VBM) was applied and multiple regression analyses for the whole sample were carried out. Clinical severity was adjusted using the Clinical Dementia Rating Sum of Boxes score (CDR-SB). A negative correlation between t-tau levels and grey matter (GM) volume in temporo-parietal regions was found, regardless of CDR-SB score. In contrast, the negative correlation between p-tau(181) and GM volume was largely explained by clinical severity, except in the posterior cingulate cortex. CR did not significantly modify these correlations. Aβ(1-42) levels were not related to GM volume but were related to clinical severity, an association that was attenuated when CR was considered. In conclusion, the present findings reflect that t-tau CSF concentrations are associated with GM atrophy in neuropathologically relevant areas across the AD continuum, whereas the p-tau(181) association is largely dependent on the degree of clinical severity. The relationship between CSF Aβ(1-42) and clinical severity seems to be modulated by CR, suggesting that there may be subjects with pathological levels of Aβ(1-42) and high CR estimates who remain clinically asymptomatic. SN - 0165-1781 UR - https://www.unboundmedicine.com/medline/citation/21546220/Association_between_cerebrospinal_fluid_tau_and_brain_atrophy_is_not_related_to_clinical_severity_in_the_Alzheimer's_disease_continuum_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0925-4927(10)00423-3 DB - PRIME DP - Unbound Medicine ER -